Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the HFA and the Working Group on Myocardial Function of the ESC

Posicionamiento de la Heart Failure Association y del ESC Working Group on Myocardial Function sobre dianas terapéuticas en miocardiopatías dilatadas e hipertróficas con causa genética.

Año: 2022
URL: Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
Referencia: Eur J Heart Fail. 2022 Mar;24(3):406-420. doi: 10.1002/ejhf.2414. Epub 2022 Jan 14.
Categoría: insuficiencia cardiaca/cardiopatía isquémica
Organismo: HFA/ESC

Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the HFA and the Working Group on Myocardial Function of the ESC

Guías Clínicas

Suscríbete

Asociaciones y Secciones

Publicaciones

Socios

Interés